Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.MZE782 has the potential to be a best-in-class therapy for patients with phenylketonuria (PKU), an inherited metabolic disorder, and a first-in-class therapy for chronic kidney disease (CKD).MAZE is reaching significant price levels. See the full breakdown here.Pharmacokinetics (PK)MZE782 demonstrated a favorable plasma PK profi ...